Evaluation of clinical efficacy of preventive therapy in pregnant women with ulcerative colitis


Keywords: preventive therapy, ulcerative colitis, pregnancy.

Abstract

Annotation. “Voluntary childlessness” as a consequence of fear of infertility, doubts about the ability to cope with pregnancy in the presence of the disease, the hereditary nature of the disease and adverse effects on the fetus; improper medication; self-modification or discontinuation of therapy in patients with CIBD (chronic inflammatory bowel disease) are significant not only medical but also social problems that currently remain unresolved. The aim of this work is to provide up-to-date evidence for the optimal diagnosis and treatment of chronic inflammatory bowel disease before conception, during pregnancy and in the postpartum period. A detailed analysis of the social, somatic, gynecological and obstetric history of women with inflammatory bowel disease was performed. The examined patients were divided into the main group (ulcerative colitis) (n=40) and control groups (almost healthy women) (n=30). The first main clinical group underwent prophylactic therapy using a drug containing active folate of the 4th generation "Quatrefolic" (equivalent to 400 μg of folic acid), potassium iodide 1 table. per day and vitamin D 1000 IU per day, starting from the planning stage of pregnancy). The second major clinical group received, in addition to Quatrefolic and potassium iodide, vitamin D 4,000 IU per day during the pre-pregnancy phase and 2,000 IU per day during pregnancy and 1,000 IU per day in cases of placental dysfunction and anemia. The formation of observation groups was carried out by methods of continuous and selective analysis. Statistical processing of research results was performed using the software package Statistica 6.0. The obtained indicators were processed statistically with the determination of the arithmetic mean (M) and the error of the standard deviation (±m), at p<0,05. Risk ratio (RR) and confidence interval (CI) were determined with a given reliable probability p=95%. Comparison of groups by case frequency was performed using the exact Fisher test (two-way criterion). Pregnant women with ulcerative colitis have a better clinical efficacy of preventive therapy using the 4th generation active folate “Quatrefolic” (equivalent to 400 mcg of folic acid) and vitamin D 4000 IU at the pre-pregnancy stage and 2000 IU after pregnancy verification compared with active folate 4th generation “Quatrefolic” (equivalent to 400 mcg of folic acid) and vitamin D 1000 IU.

References

[1] Ban, L., Tata, L. J., Humes, D. J., Fiaschi, L., & Card, T. (2015). Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther., 42(7), 855-66. doi: 10.1111/apt.13354

[2] Blumenstein I., Herrmann E., Filmann N., Zosel, C., Tacke, W., Bock, H., … & Schröder, O. (2011). Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis, 5(3), 203-10. doi: 10.1016/j.crohns.2010.12.012

[3] de Lima, A., Zelinkova, Z., Mulders, A. G., & van der Woude, C. J. (2016). Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol., 14(9), 1285-92.e1. doi: 10.1016/j.cgh.2016.03.018

[4] Huang, V., Leung, Y., Nguyen, G. C., & Seow, C. H. (2016). Management of inflammatory bowel disease in pregnancy: a practical approach to new guidelines. Can J Gastroenterol Hepatol., 2016, 9513742. doi: 10.1155/2016/9513742

[5] Mahadevan, U., McConnell, R. A., & Chambers, C. D. (2017). Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology 152(2), 451-62.e2. doi: 10.1053/j.gastro.2016.10.013

[6] McConnell, R. A., & Mahadevan, U. (2016). Pregnancy and the patient with inflammatory bowel disease: fertility, treatment, delivery, and complications. Gastroenterol Clin North Am., 45(2), 285-301. doi: 10.1016/j.gtc.2016.02.006

[7] Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., … & van der Woude, C. J. (2016). IBD in pregnancy consensus group; canadian association of gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology, 150(3), 734-57.e1. doi: 10.1053/j.gastro.2015.12.003

[8] Selinger C.P., Eaden J., Selby W., Jones, D. B., Katelaris, P., Chapman, G., … & Lal, S. (2013). Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis, 7(6), e206-13. doi: 10.1016/j.crohns.2012.09.010

[9] Toomey, D., & Waldron, B. (2013). Family planning and inflammatory bowel disease: the patient and the practitioner. Family Practice, 30(1), 64-68. doi: 10.1093/fampra/cms035

[10] Van der Woude, C. J., Ardizzone, S., Bengtson, M. B., Fiorino, G., Fraser, G., Katsanos, K., … & Magro, F. (2015). The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. Journal of Crohn’s & Colitis 9(2), 107-24. doi: 10.1093/ecco-jcc/jju006

[11] Van der Woude, C. J., Kolacek, S., Dotan, I., Øresland, T., Vermeire, S., Munkholm, P., … & Dignass, A. (2010). European evidenced-based consensus on reproduction in inflammatory bowel disease. Journal of Crohn's and Colitis, 4(5), 493-510. https://doi.org/10.1016/j.crohns.2010.07.004
Published
2021-06-24
How to Cite
Bulavenko, O. V., Oleksiienko, I. V., Prolygina, I. V., Tarasiuk, S. A., & Balabueva, S. V. (2021). Evaluation of clinical efficacy of preventive therapy in pregnant women with ulcerative colitis. Reports of Vinnytsia National Medical University, 25(2), 271-276. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2021-25(2)-15